Department of Biomedicine, University Hospital Basel, University of Basel, Switzerland; Department of Plastic, Reconstructive, Aesthetic and Hand Surgery, University Hospital Basel, Switzerland.
Department of Biomedicine, University Hospital Basel, University of Basel, Switzerland.
Acta Biomater. 2017 Nov;63:236-245. doi: 10.1016/j.actbio.2017.09.003. Epub 2017 Sep 8.
Avascular necrosis of bone (AVN) leads to sclerosis and collapse of bone and joints. The standard of care, vascularized bone grafts, is limited by donor site morbidity and restricted availability. The aim of this study was to generate and test engineered, axially vascularized SVF cells-based bone substitutes in a rat model of AVN.
SVF cells were isolated from lipoaspirates and cultured onto porous hydroxyapatite scaffolds within a perfusion-based bioreactor system for 5days. The resulting constructs were inserted into devitalized bone cylinders mimicking AVN-affected bone. A ligated vascular bundle was inserted upon subcutaneous implantation of constructs in nude rats. After 1 and 8weeks in vivo, bone formation and vascularization were analyzed.
Newly-formed bone was found in 80% of SVF-seeded scaffolds after 8weeks but not in unseeded controls. Human ALU+cells in the bone structures evidenced a direct contribution of SVF cells to bone formation. A higher density of regenerative, M2 macrophages was observed in SVF-seeded constructs. In both experimental groups, devitalized bone was revitalized by vascularized tissue after 8 weeks.
SVF cells-based osteogenic constructs revitalized fully necrotic bone in a challenging AVN rat model of clinically-relevant size. SVF cells contributed to accelerated initial vascularization, to bone formation and to recruitment of pro-regenerative endogenous cells.
Avascular necrosis (AVN) of bone often requires surgical treatment with autologous bone grafts, which is surgically demanding and restricted by significant donor site morbidity and limited availability. This paper describes a de novo engineered axially-vascularized bone graft substitute and tests the potential to revitalize dead bone and provide efficient new bone formation in a rat model. The engineering of an osteogenic/vasculogenic construct of clinically-relevant size with stromal vascular fraction of human adipose, combined to an arteriovenous bundle is described. This construct revitalized and generated new bone tissue. This successful approach proposes a novel paradigm in the treatment of AVN, in which an engineered, vascularized osteogenic graft would be used as a germ to revitalize large volumes of necrotic bone.
骨缺血性坏死(AVN)可导致骨骼和关节的硬化和塌陷。血管化骨移植物是目前的标准治疗方法,但存在供区发病率高和可用性有限的问题。本研究的目的是在 AVN 大鼠模型中生成和测试工程化、轴向血管化 SVF 细胞基骨替代物。
从脂肪抽吸物中分离 SVF 细胞,并在灌注式生物反应器系统中培养到多孔羟基磷灰石支架上 5 天。将得到的构建体插入模拟 AVN 受累骨的失活骨圆柱体内。在裸鼠皮下植入构建体时插入结扎的血管束。体内 1 周和 8 周后,分析骨形成和血管化情况。
8 周后,80%的 SVF 接种支架中发现了新形成的骨,但未接种对照支架中没有。在骨结构中的人类 ALU+细胞证明了 SVF 细胞对骨形成的直接贡献。在 SVF 接种的构建体中观察到再生性 M2 巨噬细胞密度更高。在两个实验组中,8 周后,血管化组织使失活骨恢复活力。
SVF 细胞基成骨构建体在具有临床相关大小的挑战性 AVN 大鼠模型中使完全坏死的骨骼恢复活力。SVF 细胞有助于加速初始血管化、骨形成和募集促再生内源性细胞。
骨缺血性坏死(AVN)常需要手术治疗,采用自体骨移植物,该方法手术难度大,且供区发病率高,可用性有限。本文描述了一种新型工程化的轴向血管化骨移植物替代物,并在大鼠模型中测试了其使死骨恢复活力并有效形成新骨的潜力。描述了一种临床相关大小的成骨/血管生成构建体,由人脂肪的基质血管成分与动静脉束相结合。该构建体使骨骼和关节恢复活力并生成新的骨组织。这种成功的方法提出了一种治疗 AVN 的新范例,其中工程化的血管化成骨移植物将被用作使大量坏死骨恢复活力的种子。